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ABSTRACT 
Background: FGFR3 is an actionable target in bladder cancer. Preclinical studies 
show that anti-FGFR3 treatment slows down tumor-growth suggesting that this 
tyrosine kinase receptor is a candidate for personalized bladder cancer treatment, 
particularly in patients with mutated FGFR3. We addressed tumor heterogeneity in a 
large multi-center, multi-lab study, as this may have significant impact on therapeutic 
response. 
Patients and methods: We evaluated possible FGFR3 heterogeneity by the PCR-
SNaPshot method in the superficial and deep compartments of tumors obtained by 
trans-urethral resection (TUR, n=61) and in radical cystectomy (RC, n=614) 
specimens and corresponding cancer-positive lymph nodes (LN+, n=201).  
Results: We found FGFR3 mutations in 13/34 (38%) T1 and 8/27 (30%) ≥T2-TUR 
samples with 100% concordance between superficial and deeper parts in T1-TUR 
samples. Of eight FGFR3 mutant ≥T2-TUR samples, only four (50%) displayed the 
mutation in the deeper part. We found 67/614 (11%) FGFR3 mutations in RC 
specimens. FGFR3 mutation was associated with pN0 (p<0.001) at RC. In 10/201 
(5%) LN+ a FGFR3 mutation was found, all concordant with the corresponding RC 
specimen. In the remaining 191 cases, RC and LN+ were both wild type.  
Conclusions: FGFR3 mutation status seems promising to guide decision making on 
adjuvant anti-FGFR3 therapy as it appeared homogeneous in RC and LN+. Based on 
the results of TUR, the deep part of the tumor needs to be assessed if neoadjuvant 
anti-FGFR3 treatment is considered. We conclude that studies on the heterogeneity 
of actionable molecular targets should precede clinical trials with these drugs in the 
peri-operative setting. 
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Key message: 
FGFR3 is a major potential actionable target in urothelial bladder cancer (BC). We 
found that FGFR3 mutations appeared conserved in primary BC and corresponding 
lymph-node metastases. We also showed that the deep part of the tumor needs to be 
assessed if neoadjuvant anti-FGFR3 treatment is considered. This suggests that 
personalized anti-FGFR3 therapy may improve BC treatment in the peri-operative 
setting. 
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INTRODUCTION 
Radical Cystectomy (RC) has been the gold standard for treatment of 
invasive, non-metastatic, urothelial carcinoma of the bladder (UCB) for more than 50 
years. Despite major surgery, five-year survival still only ranges from ±75% in pT2N0 
to ±25% in pN+ UCB (1,2). Peri-operative (neoadjuvant and adjuvant) platinum-
based combination chemotherapy has only marginally (5-7% overall survival benefit 
for neoadjuvant chemotherapy) improved patient’s prognosis (3-5). Consequently, 
better systemic treatment is urgently needed to improve clinical outcomes for 
invasive UCB. 
Activating oncogenic mutations of FGFR3 were identified more than 10 years 
ago in UCB (6). Interestingly, FGFR3 mutations were predominantly found in 
genetically stable UCB with a favorable prognosis (7). Moreover, FGFR3 and TP53 
mutations rarely coincide and FGFR3 mutations are, even in advanced UCB, most of 
the time accompanied by fewer molecular alterations than FGFR3 wild-type tumors 
(7-10). This indicates that FGFR3 is also a major potential actionable target in a 
subgroup of advanced UCB (9-11). Furthermore, preclinical in-vitro and in-vivo data 
show that anti-FGFR3 therapy slows down tumor growth, especially in FGFR3-
mutated tumors (12). However, the heterogeneity of FGFR3 status within a tumor or 
a patient has not been adequately addressed and may negatively impact therapeutic 
response (11). 
We report a large multi-center, multi-lab study investigating the heterogeneity 
of the FGFR3 mutations in invasive UCB. We analyzed paired samples (superficial 
and deep compartments of the same lesion) of primary trans-urethral resection 
(TUR) of 61 patients. We also analyzed paired samples from RC and positive lymph 
nodes (LN+) of 614 patients who were treated for cN0M0-UCB without prior systemic 
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chemotherapy and/or radiotherapy. FGFR3 expression was also analyzed by IHC in 
a subgroup of patients.  
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MATERIALS AND METHODS 
Study populations 
Three cohorts of patients with UCB were established to study the heterogeneity of 
FGFR3 mutation status in UCB. In total, 10 different hospitals were involved in the 
treatment of the patients and molecular analyses were done in 4 different 
laboratories.   
1. Cohort of transurethral resection (TUR): 
To evaluate intra-tumor FGFR3 mutation heterogeneity, we studied a cohort of 61 
patients who underwent a primary TUR for UCB. All tumors were primary UCB. The 
procedures were performed in 2 hospitals (Toronto; n=26 and Leeds; n=35) between 
1993 and 2006. Mean age at diagnosis was 70,3 years (SD 8,3 years); 15/61 
patients were female. All TUR specimens contained muscle as assessed by 
pathology review (TvdK and PH). For each case, a superficial and deep part of the 
same tumor specimen were separately dissected from the tissue-block or blank 
slides for DNA isolation and subsequent FGFR3 mutation analysis. All DNA-samples 
of the 61 TURs were analyzed in both labs (Toronto and Leeds) and the results were 
the same. An additional 4 TUR-cases, in which multiple parts of the same superficial 
(n=3) or invasive (n=1) areas were available, were analyzed in Toronto.  
2. Cohorts of radical cystectomy 
The second (International) cohort included 494 patients treated with radical 
cystectomy (RC) including a pelvic lymph-node dissection for cN0M0 (staged with at 
least abdominal CT and chest X-ray) UCB in 4 hospitals in Amsterdam, the 
Netherlands (n=204); Toronto, Canada (n=104); Dallas, TX, USA (n=132) and Turku, 
Finland (n=54). A previous diagnosis of non-invasive UCB was allowed. Mean age at 
RC was 65,1 years (SD 10,8 years); 121/494 patients were female. Patients were 
Page 7  
treated between 1986 and 2012 by RC without prior neo-adjuvant chemotherapy or 
pelvic radiation. Of these patients, 83/494 (17%) received adjuvant chemotherapy. 
Pathology review was done by JdJ, JS (Amsterdam) and TvdK (Toronto, Dallas, 
Turku). Node samples were available for reliable FGFR3 analysis in 117/155 pN+ 
cases. The lab in Amsterdam analyzed the 204 RC-cases from Amsterdam and the 
290 RC-cases from Toronto, Dallas and Turku were all analyzed in Toronto. 
In the third (French) cohort, 120 cN0M0 UCB patients treated in 5 French hospitals 
for locally advanced pT3/pT4 (n=100) and/or pN+ (n=99) UCB were identified. All 
these patients were treated by RC including a pelvic lymph-node dissection and 
adjuvant platinum-based chemotherapy between 2000 and 2009 at the Henri Mondor 
hospital, Créteil (n=36); the Gustave Roussy institute, Villejuif (n=28); the Curie 
institute, Paris (n=7); the Claudius Regaud institute, Toulouse (n=28) and Bergonié 
institute, Bordeaux (n=21). Mean age at RC was 62,1 years (SD 9,1 years); 16/120 
patients were female. A previous diagnosis of non-invasive UCB was allowed. None 
of the patients had prior neo-adjuvant chemotherapy or pelvic radiation. Central 
pathology review was done by YA. Node samples were available for reliable FGFR3 
analysis in 84/99 pN+ cases. The lab in Créteil analyzed all the RC-cases of the 
French cohort. 
 
Clinicopathological data collection  
The clinico-pathological characteristics, treatment and follow-up data were 
retrospectively collected. Tumors were staged according to the 2009 TNM 
classification (13) and graded according to WHO criteria. Local ethics committees 
and/or translational research boards approved the three experimental protocols and, 
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if applicable, patients provided written informed consent for central collection of their 
tissue specimens and clinical data for research purposes. 
 
Tissue (TUR & RC) specimens and DNA extraction 
Hematoxylin and eosin slides served as templates for the manual macro-dissection 
procedure on the formalin fixed, paraffin embedded tissue-block or blank slides. The 
dissected samples contained a minimum of 70% tumor cells, as assessed by 
histological examination. DNA was extracted from the tissues according to the 
manufacturer’s protocols using the DNeasy® Tissue Kit in the TUR and international 
RC cohorts. In the French RC cohort, the Maxwell® 16 FFPE Plus LEV DNA 
Purification Kit and an automated Maxwell® platform (Promega®) were used for DNA 
isolation. 
 
FGFR3 mutation analysis 
FGFR3 mutation analysis was done using the PCR-SNaPshot method in all labs. 
Details of this method were reported previously (14,15). Briefly, 3 regions (exons 7, 
10 and 15) frequently mutated and representing at least 99% of activating oncogenic 
FGFR3 mutations in UCB, were simultaneously amplified by PCR. After removing 
excess primers and deoxynucleotides, specific SNaPshot primers were annealed to 
the PCR products, separated by capillary electrophoresis and analyzed in an 
automatic sequencer (Prism® 3100 genetic analyser). With this PCR-SNaPshot 
method, a total of 11 known oncogenic FGFR3 mutations can be detected. The 
codon numbering refers to the cDNA open reading frame of the FGFR3b isoform 
expressed in epithelia (6). 
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FGFR3 expression analysis 
FGFR3 expression could be studied with IHC in 357/494 cystectomy specimens and 
in 72/117 paired RC/LN+ from the International cohort (a subset from Amsterdam, 
Toronto and Turku). Standard TMA technology was used in both labs (16). The 
available cases were routinely processed with a monoclonal antibody against FGFR3 
(FGFR3 B9, Santa Cruz, CA). Positive and negative controls were included in each 
run. Slides were assessed by BvR and TvdK (Toronto) and by BVR and JS 
(Amsterdam). A semi-quantitative scoring system was used: 0, negative; 1, 
faint/normal; 2, moderate positivity; 3, strong positivity. FGFR3 overexpression was 
defined by a score of 2 or 3 as previously described (15,17,18).  
 
Statistics 
SPSS®, version 20 was used for data documentation and analysis. Chi-square 
statistics were used to analyze possible associations between FGFR3 status and 
pathological variables. Statistical significance was set at p<0.05. 
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RESULTS 
Within the TUR cohort, FGFR3 mutations were detected in 13/34 T1 and 8/27 
≥T2 UCB, respectively. Comparing paired superficial and deep parts, no discordance 
was found within the T1-TUR samples (Figure1A), whereas discordance was 
observed in half of the cases within the ≥T2-TUR samples with only 4/8 FGFR3 
mutations in the invasive area (Figure1B). In another 4 TUR cases (one with 
mutation), multiple samples from same area (3 multiple superficial, 1 multiple 
invasive areas) were analyzed as a control experiment. We found no difference 
among these samples. 
Within the RC cohort, FGFR3 status was known for 614 RC of which 254 
(41%) were pN+. Of the 254 LN+ cases, FGFR3 status was available for 201 (79%) 
paired RC/LN+ samples. In the 614 cystectomies, 67 (11%) FGFR3 mutations were 
detected, of which 54 were pN0 (Table1). Suppl. Table1 shows the distribution of 
mutations for the International and French RC cohorts, respectively. In suppl. Table2, 
the types of FGFR3 mutations, with S249C (67%) as the most frequent one, are 
listed. Table2 shows the clinico-pathological characteristics of the 13 patients with a 
FGFR3 mutation and pN+ UCB. In the 201 paired RC/LN+ samples, the same 
FGFR3 mutation was detected in the cystectomy and LN+ specimen (Figure1C). 
Discordance between the 201 paired samples was not observed (specificity: 100%). 
The presence of a FGFR3 mutation was associated with lower pT-stage (p<0.001) 
and pN0 (p<0.001) at RC (Table1).  
Finally, FGFR3 expression was studied with immunohistochemistry (IHC) in 
357/614 cystectomy specimens (Table3a). In 280 RC, FGFR3 expression was 
normal and no mutation was found. We found 70 RC with overexpression of whom 
37 had a mutation. In 7 cases, we found a FGFR3 mutation with normal expression 
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at IHC (Table3a). IHC samples were available for 72/201 paired RC/LN+ cases 
(Table3b). FGFR3 expression was concordant in 64/72 (89%) cystectomy and LN+ 
specimens.  
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DISCUSSION 
In metastatic UCB, several targeted therapies have been evaluated as 
second-line treatment (19) but none of them has made it into the clinical practice so 
far. Although development of effective inhibitors (including anti-FGFR3 treatment) still 
is at an early stage, FGFR3 is a very promising actionable target in UCB (9-12,19). 
Comparable to other malignancies, targeted therapy has shown significant activity in 
only a minority of UCB-patients (10-12,19).  Reasons for this limited activity may 
include the diverse genomic landscape of UCB (10), the absence of molecular tumor-
analysis before test-drug administration (12) and lack of adequate studies addressing 
intra-tumor/patient heterogeneity of potential actionable targets (11). Considering 
cN0M0 patients in the peri-operative setting, molecular tumor analysis and 
heterogeneity assessment are pivotal before administering a drug against an 
actionable target. To our knowledge, the present study is the first to address tumor-
heterogeneity for the peri-operative setting in UCB with TUR and RC/LN+ specimens. 
FGFR3 activation mostly occurs via oncogenic mutations (6-12), occasionally 
by rearrangements (10,20) and also via over-expression by other mechanisms such 
as copy-number gain (10,15,17). Less is known about FGFR3 intra-tumor/patient 
heterogeneity in UCB (21). The main purpose of our multi-center, multi-lab study was 
to address this heterogeneity for the peri-operative setting of invasive UCB. Previous 
small, single center, single lab studies have shown an approximately 80% 
concordance in multiple synchronous and metachronous non-invasive UCB (17,21). 
Furthermore, recent important preclinical work provided a cellular and genetic basis 
for this diversity in UCB (22). In our study on TUR samples, we showed that FGFR3 
mutation status may differ between the superficial and invasive part of one tumor. So 
far, only one previous study reported on FGFR3 heterogeneity in superficial and 
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deep invasive parts at TUR (17). Within 18 mutated UCB, 9 had the same mutation in 
the two compartments, 8 had mutation only in the most superficial area and one had 
different mutations in the two parts. However, the authors were not sure that samples 
were from the same lesion in the bladder. In the present TUR-series, the same tumor 
was analyzed. It was notable that we found 4 cases with a FGFR3 mutation in the 
superficial part but not in the deep part of the same ≥T2 tumor. Conversely, we did 
not observe a difference in FGFR3 status in 201 RC and LN+ samples of our RC 
cohort. Therefore, it is likely that, at RC, the deep part of the tumor has been 
analyzed and that the superficial part was already removed by the preceding TUR. 
The mutation frequency at RC (11%) also corresponded to the mutation frequency of 
the deep part of the ≥T2-TUR cohort (15%). The frequency of FGFR3 mutations 
(12%) in the TCGA-cohort of 131 high-grade muscle-invasive UCB (mostly 
cystectomy specimens) was also comparable to our cohort. This implies that the 
deep part of the tumor at TUR needs to be assessed if neoadjuvant anti-FGFR3 
treatment is considered.  
Our study showed that, if a mutated clone progresses in MI-UCB, the FGFR3 
mutation is conserved in the invasive compartment and also in the metastatic node 
despite the notion that not all the lesions in the RC cohorts were primary (first 
diagnosis) UCB. We also reported that the FGFR3 mutation was associated with 
lower T-stage and pN0 at RC. Others have already reported that FGFR3 mutations 
are also in MI-UCB most of the time not accompanied by many other molecular 
alterations (8,10). Taken together, all these findings suggest that anti-FGFR3 
treatment may have significant clinical impact in the peri-operative setting for a 
relative small subgroup of MI-UCB patients. 
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FGFR3 expression is another way to explore FGFR3 activity. Turo et al. (18) 
recently reported a heterogeneity study using FGFR3 expression by IHC without 
FGFR3 mutation evaluation. In their cohort, paired RC/LN+ samples were available 
for IHC analysis in 106/150 pN+-UCB and concordance was found in 79/106 (75%) 
cases. We here reported IHC-concordance in 64/72 (89%). Previous IHC studies 
showed that approximately 40% of invasive FGFR3 wild-type tumors overexpress 
FGFR3 suggesting an alternative mechanism to activate FGFR3 (10,15,17). In our 
RC-series, only 10% of wild-type cases showed overexpression (Table3). One of the 
reasons for this lower percentage might be that we analyzed RC specimens and 
consequently deeper parts of the tumor than in the previous studies. Nevertheless, 
we can’t exclude that a small subset of patients with wild-type tumors may still benefit 
from anti-FGFR3 treatment. On the other hand, we showed that FGFR3 mutation 
analysis was extremely robust across 4 labs. IHC is likely more prone to observer 
variability than FGFR3 mutation analysis making it less appropriate to assess FGFR3 
heterogeneity within a tumor or metastases of a patient. Future study should focus on 
how to combine FGFR3 mutation, translocation and copy-number status with 
FGFR3-IHC to guide optimal personalized anti-cancer treatment. 
In conclusion, we found that FGFR3 mutations appeared conserved in primary 
bladder cancer and corresponding lymph-node metastases. Hence, anti-FGFR3 
treatment may have significant clinical impact in the adjuvant setting. We also 
showed that the deep part of the tumor needs to be assessed if neoadjuvant anti-
FGFR3 treatment is considered. Our data on tumor heterogeneity suggest that 
personalized anti-FGFR3 therapy may improve bladder cancer treatment for a 
relatively small, well-selected subgroup of invasive UCB patients. Studies on the 
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heterogeneity of actionable molecular targets should precede clinical trials with these 
drugs in the peri-operative setting. 
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FIGURE LEGEND 
Legend Figure 1 
Figure 1 shows the distributions of FGFR3 mutations in the superficial and deep 
compartments of the 61 (34 T1 and 27 ≥T2) patients included in the trans-urethral 
resection (TUR) cohort and in the 614 radical cystectomy patients with 201 paired 
cystectomies and metastatic nodes available.  
A: The 13 mutated cases in 34 paired T1-TUR samples are displayed. Both parts 
(superficial and deep) were wild type in 21 cases.  
B: The 8 mutated cases in paired ≥T2-TUR samples are displayed. Both parts 
(superficial and deep) were wild type in 19 cases. 
C: The 10 mutated cases in paired cystectomies and metastatic nodes are displayed. 
The cystectomy and metastatic node were both wild type in 191 cases. 
 
 
 
 
 



TABLES 
 
Table 1 – The distribution of samples according to the primary tumors pathologic pT-
stage and FGFR3 mutation status among either N0 or N+ cases in the radical 
cystectomy cohort. FGFR3 mutations were associated with lower pT-stage (p<0.001) 
and pN0 (p<0.001) at radical cystectomy.   
 
 
 
 
 pTa, pT1, pTis pT2 pT3 pT4 Total 
N0 
Wild type 47  93  118  48  306  
Mutated 23  11  14  6  54  
N+ 
Wild type 5  46  127  63 241  
Mutated 0  0  6  7  13 
Total 75  150  265  124  614 
 
 
 
Table 2 - Clinical and pathological characteristics of patients with pN+ UC and a FGFR3 mutation detected in cystectomy and/or 
positive lymph node. In 3 cases, the node sample was not available. 
Patient Age Gender Histology Pathological 
stage 
WHO1973 
grade 
AC Relapse Relapse 
type 
Vital 
status 
Follow-
up (yr.) 
Disease 
status 
FGFR3 
mutation 
Mutated 
samples 
Int711 73 M UC pT4aN2 3 No Yes DM Dead 1.7 DOD S249C T,N 
Int1008 44 F UC+SCC pT4aN2 3 No No - Alive 0.7 FOD S249C T 
Int1015 39 M UC pT4aN2 3 No Yes DM Alive 1.1 FOD S249C T 
Int1028 78 F UC pT4aN2 2 Yes No - Alive 1.5 FOD S249C T,N 
Int3097 56 F UC pT3bN2 3 No Yes DM Dead 1.2 DOD R248C T,N 
Int3113 78 M UC+SCC pT3aN2 3 No No - Alive 9.4 FOD S249C T,N 
Int3125 75 M UC pT3aN1 3 No Yes DM Dead 1.1 DOD S249C T 
Int3180 62 F UC+SCC pT4bN2 3 No Yes DM Dead 0.4 DOD S249C T,N 
Int3280 81 F UC pT3bN2 3 No Yes DM Dead 1.9 DOD R248C T,N 
VCA023 77 M UC pT3aN1 3 Yes No - Alive 2 FOD S249C T,N 
VCA045 46 M UC pT3bN2 3 Yes Yes DM Dead 3.6 DOD S249C T,N 
VCA047 56 M UC pT4aN1 3 Yes No - Alive 11 FOD S249C T,N 
VCA090 59 M UC pT4aN2 3 Yes Yes DM Dead 2.6 DOD S249C T,N 
AC: Adjuvant Chemotherapy; M: Male; F: Female; UC: Urothelial Carcinoma; UC+SCC: Urothelial carcinoma with squamous 
differentiation; T: Tumor; N: Node; DM: Distant Metastasis; FOD: Free of Disease; DOD: Dead of Disease.  
Table 3a - FGFR3 expression and FGFR3 mutation (cystectomy specimens) in a subset of 357/494 cases from the 
international radical cystectomy cohort. 
 
 
 FGFR3 expression in cystectomy Total 
Normal Over-expression 
FGFR3 mutation in 
cystectomy 
Wild type 280 33 313 
Mutated 7 37 44 
Total 287 70 357 
 
 
 
 
 
Table 3b - FGFR3 expression in cystectomy and corresponding metastatic lymph nodes in a subset of 72/117 pN+ cases from the 
international radical cystectomy cohort. 
 
 
 
 FGFR3 expression in cystectomy  
Normal Over-expression Total 
FGFR3 expression in positive 
node 
Normal 57 4 61 
Over-expression 4 7 11 
 Total 61 11 72 
 
 
SUPPLEMENTALS – Online Only 
 
Supplemental Table 1 - Distribution (frequencies) of samples according to the primary tumors pathologic stage and FGFR3 
mutation status among either N0 or N+ cases in the International (A) and French (B) cohorts. Please note that adjuvant 
chemotherapy was given to all the patients in the French cohort and to 83/494 (17%) patients in the international cohort. 
A pTa, pT1, pTis pT2 pT3 pT4 Total 
N0 
Wild type 47  93  106  40  286  
Mutated 23  11  14  5  53  
N+ 
Wild type 2  29  81  34 146  
Mutated 0  0  4  5  9  
Total 72  133  205  84  494 
 
B pTa, pT1, pTis pT2 pT3 pT4 Total 
N0 
Wild type 0  0  12  8  20  
Mutated 0  0  0  1  1  
N+ 
Wild type 3  17  46  29  95  
Mutated 0  0  2  2  4  
Total 3  17  60  45  120 
Supplemental Table 2 - FGFR3 mutation type in 67 mutated radical cystectomy 
samples. The FGFR3 mutations G372C, A393E, K652M, K652T, K652E and K652Q 
were not detected in this radical cystectomy series. Of note, the types of FGFR3 
mutations in the TUR series (n=21) can be derived from Figure 1. 
 
FGFR3 mutation type Mutations (%) 
 
R248C 
  
 9  (13%) 
S249C                             45  (67%) 
S373C 1   (2%) 
Y375C 11  (16%) 
G382R 1   (2%) 
  
Total:     67   (100%) 
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